# Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

> **NCT04965064** · PHASE2 · RECRUITING · sponsor: **University of Rochester** · enrollment: 22 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Capecitabine and Neratinib.

## Key facts

- **NCT ID:** NCT04965064
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-23
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04965064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04965064, "Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04965064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*